HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
Sample Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1636
Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table...  read more...
More from issue 1636
Advance Release
Coming Soon
Antiviral Drugs for Influenza for 2021-2022
Drugs for Rheumatoid Arthritis
Ruxolitinib (Opzelura) for Atopic Dermatitis
Clascoterone 1% Cream (Winlevi) for Acne
Recommend to Your Library  
Previous Issues
© 2021 The Medical Letter, Inc.